• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Radoff-Sudbury Group Sets the Record Straight and Highlights Key Facts that Reinforce the Need for Targeted Boardroom Change at LifeVantage Corporation

    10/19/23 5:00:00 PM ET
    $EGY
    $FTLF
    $LFVN
    Oil & Gas Production
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $EGY alert in real time by email

    Exposes the Misrepresentations and Distortions Included in LifeVantage's Recent Presentation

    Believes Recent Misleading Statements from "Independent" Directors Underscore Chairman Garry Mauro's Outsized Influence Over LifeVantage, Where He Has Served as a Director for Over 15 Years

    Encourages Stockholders to Review the Radoff-Sudbury Group Investor Presentation and Vote for Nominees Dayton Judd, Michael Lohner and Bradley L. Radoff on the BLUE Proxy Card Ahead of the Upcoming Annual Meeting on November 6th

    Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group," "we" or our "Group"), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), today responded to the misrepresentations and distortions included in the Company's recently issued presentation. Dayton Judd, Michael Lohner and Bradley L. Radoff have been nominated by the Radoff-Sudbury Group for election to LifeVantage's Board of Directors (the "Board") at the upcoming Annual Meeting of Stockholders (the "Annual Meeting") currently scheduled for November 6, 2023.

    As a reminder, the Radoff-Sudbury Group recently filed its own presentation detailing why the Radoff-Sudbury Group believes that LifeVantage is in urgent need of new perspectives in the boardroom following years of poor performance and governance under long-tenured directors Chairman Garry Mauro, Michael Beindorff and Darwin Lewis.

    The Radoff-Sudbury Group commented:

    "LifeVantage's recent investor presentation and self-serving statements publicized by Board members fail to directly respond to the concerns we have raised and only reinforce that fresh perspectives are desperately needed in the boardroom. Based on the presentation's contents and misleading information that attempts to justify the Company's poor capital allocation and corporate governance practices, it is apparent that the Board is unwilling to consider new perspectives and do what is right for long-suffering stockholders. The Board is conveniently ignoring the indisputable fact that LifeVantage stockholders have endured over a decade of dismal performance – destroying 70% in stockholder value under Mr. Mauro's reign as its 10-year Chairman. We question why the current directors are so resistant to adding new voices to the Board and steadfast in their resolve to stand by Mr. Mauro and his indefensible track record. We encourage our fellow stockholders to see through LifeVantage's smokescreens and entrenchment tactics and evaluate the facts before deciding which slate of director candidates would truly put stockholders' best interests first."

    LIFEVANTAGE MISINFORMATION VS. THE FACTS

    Financial Performance and Consultant Attrition

    LifeVantage's Myth

    The Facts

    • "Our New Plan Has Driven Outperformance… We believe that our improved relative total shareholder return ("TSR") reflects our progress under our rebuilt leadership team and new LV360 strategy"

     

    • Despite claims that the Board's "transformation plan" is working, LifeVantage has continued to deliver poor financial performance.

     

    • The Company reported a drop in earnings per diluted share from $0.79 in fiscal year 2020 – when the so-called "transformation plan" was supposedly initiated – to $0.20 per share in fiscal year 2023.

     

    • Stockholders that invested their money in the Company as recently as 2020 have lost 61% in the value of their investment.1
    • "Since the pandemic, we significantly transformed the business, starting with a new CEO who restructured the entire management team and worked with the Board to develop a sustainable strategy for long-term success"

     

    • The so-called "transformation plan" has resulted in a 73% year-over-year decline and a 17% year-over-year decline in EPS in 2022 and 2023, respectively.

     

    • The Board – under Mr. Mauro's leadership as Chairman – has overseen a decline in TSR of 70% over the past decade.2
    • "… Consultants [could] lose confidence in the Company and destabilize the business at a critical time… we developed an industry-leading direct selling compensation program for consultants and customers, a state-of-the-art customer loyalty program, launched several new successful products, developed new digital tools and an enhanced app and entered new international markets"

     

    • LifeVantage's independent consultant base has been in rapid decline. Since 2020, the Company has seen a 26% decline in consultants, a 16% decline in customers and a 20% decline in active accounts.

     

    • These concerning declines underscore the need to install proven operators with direct selling experience in LifeVantage's boardroom.

     

    • In fact, we have received unsolicited messages from consultants who have indicated that they hope to see change implemented at the Board-level.

    Capital Allocation Decisions

    LifeVantage's Myth

    The Facts

    • "Our Major League Soccer Sponsorship is Valuable… The annualized cost of LifeVantage's sponsorship deal with Real Salt Lake ("RSL") is currently the lowest in Major League Soccer… Our relationship with RSL has helped drive customer and consultant interest in our brand and enabled us to compete more effectively with the many other direct selling companies that have also sponsored teams and stadiums"

     

    • In 2013, the 10-year, $30 million deal was reported to be "one of the league's largest" deals ever inked.3

     

    • LifeVantage has been dealing with significant consultant and customer attrition issues, so clearly the costly investment in the soccer sponsorship and associated advertising has not paid off and was a waste of stockholder dollars.

     

    • This was a poorly thought-out investment, based on the drag on the Company's bottom line and its decision not to extend the sponsorship.
    • "Our Office Lease Is Market-Priced… Our new office space, which we opened in 2021, is an important part of our strategy … Importantly, the rent per square foot for our office is in-line with city-wide rates for Class A office space in Salt Lake City" 

     

    • We question the Board's decision to commit to a $17.3 million lease for office space when the majority of its revenue-generating workforce is its consultants.

     

    • LifeVantage fails to acknowledge it is located outside of Salt Lake City while comparing the lease to city rates.

     

    • Even so, LifeVantage is paying a premium per square foot compared to the average asking price in the region and will pay nearly $2 million in one year alone for just two floors of office space.

    Corporate Governance Issues

    LifeVantage's Myth

    The Facts

    • "The Board is comprised of seven engaged directors with an average tenure of 6.5 years who collectively own approximately 7% of LifeVantage stock"

     

    • The directors we are seeking to replace on the Board have excessively long tenures for public company directors: Mr. Mauro for an astounding 15+ years, Mr. Beindorff for nearly 12 years and Mr. Lewis for over 6.5 years.

     

    • Our Group owns nearly twice as much stock as the entire Board combined and almost all the shares owned by the current directors were granted to them rather than purchased on the open market – underscoring the Board's lack of alignment with stockholders.

     

    • Of the 6.54% of stock the Board collectively owns, approximately 6% was granted to them through stock awards.
    • "We gave proper notice of the original September 15 record date… When we needed to amend it to allow for more time to prepare our proxy materials, we gave more than three weeks' advance notice of the delayed record date of September 27…"

     

    • The Board admits it failed to provide proper notice of the September 27 record date for the upcoming Annual Meeting, in violation of U.S. Securities and Exchange Commission ("SEC") Rule 14a-13(a)(3).

     

    • The Board appears to have intentionally manipulated the Company's corporate machinery to influence the voting outcome at the upcoming Annual Meeting by buying itself more time to attempt to place shares into friendly hands or otherwise game the system in the Company's favor.
    • "The Radoff-Sudbury Group is referring to a proxy solicitor call script which merely invites shareholders to call our proxy solicitor and contains no substance…"

     

    • The Board failed to properly file this, among other stakeholder communications with the SEC, violating SEC Rule 14a-6.

     

    • We find it highly concerning that the Board appears to have intentionally avoided filing certain communications with the SEC in an apparent effort to create an uneven playing field and sway how stockholders will vote at the upcoming Annual Meeting. The Board's habitual and repeated violations of SEC regulations show an apparent disregard for securities law and stockholders' interests.
    • "Mr. Mauro is not currently acting as a stockbroker, but he remains licensed and has all the qualifications to do so if he associates with another broker-dealer"

     

    • A public record search shows that Mr. Mauro apparently has not been a registered financial professional with FINRA or the SEC since 2021 despite claims of being a licensed stockbroker in his proxy bio.

     

    • Mr. Mauro's inclusion that he is "a licensed stockbroker" in his proxy bio filed with the SEC is not only inaccurate but also misleading.
    • "Mr. Radoff also complains that the targeted directors do not have sufficient share ownership, but each of those three directors owns more stock than Mr. Radoff owns at Harte-Hanks and Farmer Brothers, where he serves as a director"

     

    • This statement is categorically false. According to the latest proxy statements of each company, Mr. Radoff personally owns nearly 3% of Harte-Hanks, Inc. and ~2% of Farmer Bros. Co.'s outstanding shares, which is more than all three targeted directors' stake in LifeVantage.

     

    • The directors we are seeking to replace own a de minimis amount of LifeVantage stock. Messrs. Beindorff, Lewis and Mauro respectively own just 0.87%, 0.70% and 1.49% of the Company's outstanding shares – with nearly all being granted to them through stock awards.

    The Radoff-Sudbury Group's Intentions

    LifeVantage's Myth

    The Facts

    • "In over two years of engagement, the members of the Radoff-Sudbury Group have failed to offer any substantive recommendations for improving our business"

     

    • Since our engagement began over two years ago, we have offered clear solutions on how to improve LifeVantage's corporate governance and performance for the benefit of all stakeholders – including Mr. Judd's rebuffed offer to present his views directly to the Board.

     

    • Our Group made numerous good-faith attempts to work constructively with the Board to avoid a proxy contest.

     

    • Despite representing the largest LifeVantage stockholder, our Group was met with resistance from the Board, who refused to meaningfully consider our nominees and made various defense maneuvers and entrenchment tactics in direct response to our feedback.
    • "[Mr. Radoff] has a large ownership stake in a competitive business, creating conflicts of interest and potential loyalty issues"

     

    • As successful investors, Messrs. Radoff and Judd are passive owners in other companies, which does not preclude them from serving on LifeVantage's Board.

     

    • Messrs. Radoff and Judd are collectively the largest stockholder of LifeVantage – owning 12.8% – meaning their interests are squarely aligned with the Company's owners: creating sustainable, long-term value.
    • "The election of the Radoff-Sudbury candidates would remove valuable skills and critical leadership from the Board at a vital time during the Company's complex business transformation"

     

    • Messrs. Beindorff, Lewis and Mauro do not possess audit, financial or capital allocation experience, and have overseen poor capital allocation decisions, including the $30 million MLS deal, an irresponsible, 11-year $17 million office lease and questionable related party transactions.

     

    • We have nominated a slate of highly qualified individuals – including two Audit Chairs – with extensive financial, direct selling and wellness industry expertise to address experience gaps in the boardroom.

     

    • Our slate has a track record of value creation. Mr. Lohner has applicable industry experience as an investor and executive of direct selling companies. Meanwhile, Mr. Judd delivered 1,951% in stockholder value while serving as the CEO and a director of FitLife Brands Inc. (NASDAQ:FTLF) and Mr. Radoff delivered 239% in stockholder value while serving as a director at VAALCO Energy, Inc. (NYSE:EGY).4
    • "Replacing half of our independent directors with individuals…"

     

    • This is a misleading statement, as our Group is seeking to replace three directors on LifeVantage's seven-member board.

     

    • If elected to the Board by stockholders, our nominees would represent a minority.
    • "…the Radoff-Sudbury Group has refused to permit its candidates to even interview absent a commitment from us ahead of time that two of our six independent directors will retire from the Board by the 2024 Annual Meeting"

     

    • The Radoff-Sudbury nominees indicated that given LifeVantage's recent defensive actions – including the harassing letter delivered directly to Mr. Lohner's employer just two days prior – they did not believe the interview request was made in good faith.

     

    • Nevertheless, the Radoff-Sudbury nominees did complete and deliver LifeVantage's D&O Questionnaires and Messrs. Judd and Radoff indicated a willingness to meet with the Nominating and Corporate Governance Committee directly to express their views.

     

    • The Board made clear through our discussions its unwillingness to constructively engage with us on any meaningful Board refreshment until at least 2027.

    ***

    VOTE "FOR" THE HIGHLY QUALIFIED RADOFF-SUDBURY NOMINEES ON THE BLUE PROXY CARD AHEAD OF LIFEVANTAGE'S UPCOMING ANNUAL MEETING ON NOVEMBER 6, 2023.

    ONLY YOUR LATEST DATED VOTE COUNTS. IF YOU VOTED FOR THE COMPANY'S NOMINEES PREVIOUSLY, A LATER DATED VOTE FOR THE RADOFF-SUDBURY NOMINEES WILL OVERRIDE YOUR PRIOR VOTING INSTRUCTIONS.

    IF YOU HAVE ANY QUESTIONS REGARDING HOW TO VOTE, PLEASE CALL SARATOGA PROXY CONSULTING AT (888) 368-0379 OR (212) 257-1311 OR BY EMAIL AT [email protected].

    PLEASE KNOW THAT BOTH YOUR INTERACTION WITH OUR PROXY SOLICITOR AND YOUR VOTING DECISION ARE COMPLETELY CONFIDENTIAL.

    1 Three-year TSR calculated as of market close on August 10, 2023, the last day prior to the public announcement of the nomination of the Radoff-Sudbury Nominees.

    2 10-year TSR calculated as of market close on August 10, 2023, the last day prior to the public announcement of the nomination of the Radoff-Sudbury Nominees.

    3 Source: Sports Business Journal, Real Salt Lake Announces LifeVantage Will Supplant Xango As Jersey Sponsor.

    4 Source: Bloomberg. FTLF TSR calculated from February 18, 2018 through October 6, 2023. EGY TSR calculated from June 25, 2020 through January 28, 2022.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231019182614/en/

    Get the next $EGY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EGY
    $FTLF
    $LFVN

    CompanyDatePrice TargetRatingAnalyst
    FitLife Brands Inc.
    $FTLF
    3/17/2025$21.00Buy
    Lake Street
    Lifevantage Corporation
    $LFVN
    1/14/2025$35.00Buy
    Craig Hallum
    Lifevantage Corporation
    $LFVN
    12/19/2024$26.00Buy
    Lake Street
    FitLife Brands Inc.
    $FTLF
    9/3/2024$40.00Buy
    ROTH MKM
    VAALCO Energy Inc.
    $EGY
    3/1/2023Buy
    Stifel
    More analyst ratings

    $EGY
    $FTLF
    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cunningham Kristen

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:06 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Neufeld Alissa

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:07 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aure Carl

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:06 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGY
    $FTLF
    $LFVN
    SEC Filings

    View All

    FitLife Brands Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    4/7/26 4:23:40 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    4/1/26 8:00:13 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by FitLife Brands Inc.

    10-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    3/31/26 4:30:39 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $EGY
    $FTLF
    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results

    OMAHA, NE, April 01, 2026 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the fourth quarter and full year ended December 31, 2025. Highlights for the fourth quarter ended December 31, 2025 include: Total revenue was $25.9 million, an increase of 73% compared to the fourth quarter of 2024.  Wholesale revenue was $15.5 million, or 60% of total revenue, an increase of 213% compared to the fourth quarter of 2024.Online revenue was $10.5 million, or 40% of total revenue, an increase of 4% compared to the fourth quarter of 2024.Excl

    4/1/26 7:00:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Fourth Quarter Earnings Call

    OMAHA, NE, March 30, 2026 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the fourth quarter of fiscal 2025 on Tuesday, March 31, 2026. In addition, the Company announced that it will hold an investor conference call after market close on April 1, 2026 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 115536.  International participants can dial (973) 528-0163 and provide the same code. A

    3/30/26 11:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    LifeVantage to Participate in the Sidoti Small Cap Conference

    SALT LAKE CITY, March 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the Sidoti Small Cap Conference, to be held March 18-19, 2026. Mr. Fife and Mr. Aure will meet virtually with investors and present at approximately 4:00 p.m. Eastern Time on Thursday, March 19, 2026. A live webcast of their presentation will be accessible on the News & Events section of the Company's Investor Relations website at https://lifevantage.gcs

    3/16/26 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGY
    $FTLF
    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation

    SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of Mike Edwards as Chief Technology Officer. Edwards brings more than 25 years of experience as an accomplished senior executive specializing in technology leadership and enterprise transformation. "Mike is a strategic leader with a strong track record of translating technological innovation into measurable business impact and we are delighted to have him join the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "His expertise in eCo

    1/7/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FitLife Brands Announces Board Transition

    Omaha, NE, April 28, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced today the resignation of Todd Ordal as a member of the Company's Board of Directors. Mr. Ordal's resignation, effective on April 25, 2025, was part of the Company's ongoing commitment to refresh board composition on a regular basis in accordance with good corporate governance practices and was not the result of any disagreement with the Company's management or the Board of Directors regarding any matter related to the Company or otherwise. On April 25, 2025, the Board of Directors of

    4/28/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $EGY
    $FTLF
    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by VAALCO Energy Inc.

    SC 13G/A - VAALCO ENERGY INC /DE/ (0000894627) (Subject)

    11/12/24 5:48:11 PM ET
    $EGY
    Oil & Gas Production
    Energy

    Amendment: SEC Form SC 13G/A filed by VAALCO Energy Inc.

    SC 13G/A - VAALCO ENERGY INC /DE/ (0000894627) (Subject)

    11/4/24 1:49:18 PM ET
    $EGY
    Oil & Gas Production
    Energy

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGY
    $FTLF
    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dayton Judd bought $152,422 worth of shares (33,197 units at $4.59), increasing direct ownership by 70% to 80,359 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    3/2/26 6:44:28 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $5,265 worth of shares (805 units at $6.54), increasing direct ownership by 0.62% to 131,553 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/17/25 4:23:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGY
    $FTLF
    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on FitLife Brands with a new price target

    Lake Street initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $21.00

    3/17/25 8:22:47 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGY
    $FTLF
    $LFVN
    Financials

    Live finance-specific insights

    View All

    FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results

    OMAHA, NE, April 01, 2026 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the fourth quarter and full year ended December 31, 2025. Highlights for the fourth quarter ended December 31, 2025 include: Total revenue was $25.9 million, an increase of 73% compared to the fourth quarter of 2024.  Wholesale revenue was $15.5 million, or 60% of total revenue, an increase of 213% compared to the fourth quarter of 2024.Online revenue was $10.5 million, or 40% of total revenue, an increase of 4% compared to the fourth quarter of 2024.Excl

    4/1/26 7:00:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Fourth Quarter Earnings Call

    OMAHA, NE, March 30, 2026 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the fourth quarter of fiscal 2025 on Tuesday, March 31, 2026. In addition, the Company announced that it will hold an investor conference call after market close on April 1, 2026 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 115536.  International participants can dial (973) 528-0163 and provide the same code. A

    3/30/26 11:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    VAALCO Energy, Inc. Announces Fourth Quarter and Full Year 2025 Results

    HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE:EGY, LSE: EGY)) ("Vaalco" or the "Company") today reported operational and financial results for the fourth quarter and full year of 2025, including year-end 2025 reserves. Additionally, the Company provided operational and financial guidance for the first quarter and full year of 2026. 2025 Full Year Highlights: Sold 17,452 net revenue interest ("NRI")(1) barrels of oil equivalent per day ("BOEPD"), above the high end of the Company's increased guidance, while delivering production of 16,556 NRI(1) BOEPD or 21,160 working interest ("WI")(2) BOEPD, both above the midpoint of Vaalco's increased guidance;Reported full ye

    3/12/26 4:45:00 PM ET
    $EGY
    Oil & Gas Production
    Energy